BACKGROUND {#sec1-1}
==========

Gliosarcoma (GS) is a primary rare malignant brain tumor that contains both gliomatous and sarcomatous (mesenchymal) components and accounts 4% of all high-grade glial tumor of the brain.\[[@ref6]\] Based on the 2007 World Health Organization (WHO) classification, GS is a Grade 4 tumor same as glioblastoma multiform (GBM).\[[@ref8]\] In the literature, mean overall survival (OS) of GS in untreated patients is 4 months and with multidisciplinary tri-modal therapy, the mean OS is about 15 months.\[[@ref10]\] We present a patient with GS that we treated her and she has 50 months disease-free survival up to now.

CASE DESCRIPTION {#sec1-2}
================

We present a 45-year-old female admitted to our center with progressive headache since 1 month ago concomitant with nausea, emesis, and generalized weakness. She had minimal headache since 2 years ago and, on admission clinical examination, we did not find any neurologic deficits. Also, the patient had bilateral pupillary edema on fundoscopy. She had bilateral positive Hoffmann\'s sign. On first brain computed tomography (CT), we saw a large heterogeneous mass with some vasogenic edema at right parieto-occipital region with 0.5 cm midline shift that compressed right occipital horn of lateral ventricle \[[Figure 1a](#F1){ref-type="fig"}\]. The brain magnetic resonance imaging (MRI) with and without gadolinium (Gd) revealed a large solid mass with well-defined margin and some cystic portions that enhanced brightly with Gd \[Figure [1b](#F1){ref-type="fig"} and [c](#F1){ref-type="fig"}\]. The vasogenic edema was less than our expectation.

![Preoperative brain computed tomography scan (a) of the patient revealed a large heterogeneous mass at right parieto-occipital region with some vasogenic edema that produces a 0.5 cm midline shift of the brain. On the brain magnetic resonance imaging, we found a solid-cystic hyper-intense mass on T2 sequences (b) that it is brightly enhanced after injection of gadolinium (c). Follow-up brain magnetic resonance imaging with gadolinium revealed no remnant of tumor (d)](SNI-9-227-g001){#F1}

According to very large mass effect, we decided to operate the patient via right parietal craniotomy. The tumor had a more firm consistency compared with adjacent normal brain tissue and it was well demarcated and we totally resected all visible portions of the mass, as en bloc resection. The histopathological report of the mass was GS \[Figure [2a](#F2){ref-type="fig"}--[d](#F2){ref-type="fig"}\]. After surgical treatment, the patient\'s treatment continued by chemotherapy with temozolamide and a course of radiotherapy. We are following the patient up to now, for about 50 months, and she is good without any compliant or neurologic deficit. All follow-up MRI did not show any tumor recurrence \[[Figure 1d](#F1){ref-type="fig"}\].

![Histopathologic finding revealed a biphasic tumor with alternating between glial and mesenchymal differentiation (a, H and E × 400). Immunohistochemically (IHC), we see G-FAP positive portions (negative for reticulin, b × 100) and in concomitant with reticulin-riched portions (negative for G-FAP, c × 400) in other sites. Also, we can see positive staining for Ki-67 (d × 400)](SNI-9-227-g002){#F2}

DISCUSSION {#sec1-3}
==========

The GS, as known Feigin tumor, is a rare and malignant glioma.\[[@ref3]\] With best existing tri-modal therapy, contained surgical gross total resection and then chemoradiotherapy, this tumor has very poor prognosis.\[[@ref10]\] For GS, histopathological exam shows both gliomatous and sarcomatous components. At the surgery compared with GBM, the borders of tumor are more distinct because of presence of sarcomatous component, but on the other hand, the patients have less response to adjuvant treatment contained chemotherapy and radiotherapy during postoperative period.

In the literature, we found only eight reports of GS with OS \>2 years \[[Table 1](#T1){ref-type="table"}\]. Considering the term of survival, we have to pay attention to this subject that the "overall survival" is different with "progression-free survival" (PFS). The patients with longer OS have not necessarily longer PFS and they may have multiple recurrence period needed complete treatment courses that patients suffered from them. Longer PSF can predict more excellent quality of life (QOL). Compared with our case, only four reports of GS had a longer OS concomitant with long PFS.\[[@ref1][@ref4][@ref9][@ref10]\]

###### 

A literature review for all reported cases with GS and longer OS

![](SNI-9-227-g003)

Although in almost all cases, infiltrative nature of gliomatous tumors hinder to remove all portions of them, because of sarcomatous components of GS, differences in consistency of tumoral tissue compared with brain tissue assist to define a relatively well-demarcated plane between them during surgery. In addition, en bloc resection with preservation of tissue planes during dissection prevents missing any tumor component intermingled with brain parenchyma at the time of dissection. Finally, location of the lesion in non-eloquent area of brain lets intraoperative manipulations and more feasible en bloc tumor removal. We think all these factors together in association with appropriate and timely adjuvant therapy helps surgeon to give the most chance of PFS to the patient with GS.

CONCLUSION {#sec1-4}
==========

We present a patient with GS that has a long PFS after surgical treatment. Aiming to achieve longer PFS in cases of GS and regarding to more distinct consistency, we recommend resecting all portions of the mass, as much as possible, to reach en bloc resection and then refer the patients for appropriate and timely chemoradiotherapy.
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